



SPARC/Sec/SE/2022-23/117

March 24, 2023

To,
BSE Limited,
Market Operations Dept.
P.J. Towers
Dalal Street
Mumbai 4000001

Scrip Code: 532872

Dear Sir/Madam,

Sub: Clarification – Increase in Volume

Ref: Email dated March 24, 2023 bearing reference no L/SURV/ONL/PV/VK/ 2022-2023 / 469

With reference to above referred letter, we confirm that the Company is in compliance with the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and that all the disclosures required to be made under the said regulation have been made to the exchanges. We are not aware of any information which qualifies to be disclosed under the said regulation but have not been disclosed.

We remain committed to make adequate and timely disclosures to the Stock Exchanges in compliance with the applicable regulations.

We request you to kindly take the same on record.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

Chetan Rajpara
Chief Financial Officer

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life

Registered office : Plot no. 5&6/1, Savli GIDC Estate, Manjusar 391775, District: Vadodara, Gujarat, India.